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The serine threonine protein kinase, Akt, is at the central hub of signaling pathways that reg-
ulates cell growth, differentiation, and survival. The reciprocal relation that exists between
the two activating phosphorylation sites of Akt, T308 and S473, and the two mTOR com-
plexes, C1 and C2, forms the central controlling hub that regulates these cellular functions.
In our previous review “PI3Kinase (PI3K)-AKT-mTOR and Wnt signaling pathways in cell
cycle” we discussed the reciprocal relation between mTORC1 and C2 complexes in regu-
lating cell metabolism and cell cycle progression in cancer cells. We present in this article,
a hypothesis that activation of Akt-T308 phosphorylation in the presence of high ATP:AMP
ratio promotes the stability of its phosphorylations and activates mTORC1 and the energy
consuming biosynthetic processes. Depletion of energy leads to inactivation of mTORC1,
activation of AMPK, FoxO, and promotes constitution of mTORC2 that leads to phospho-
rylation of Akt S473. Akt can also be activated independent of PI3K; this appears to have
an advantage under situations like dietary restrictions, where insulin/insulin growth factor
signaling could be a casualty.
Keywords: FoxO, rictor, Akt, insulin/IGF signaling, glucose transport
INTRODUCTION
Protein kinases have been implicated in affecting many aspects
of metabolism and cell fate and play key roles in the pathogene-
sis of human diseases, including metabolic disorders, degenerative
diseases, and cancer. Akt or Protein kinase B was discovered in the
year 1991, as a novel serine threonine (ser/thr) protein kinase, by
three independent groups. It was variously named as rac protein
Abbreviations: AH/PH domain, a unique N-terminal domain of the AKT protein
which contains pleckstrin homology domain for binding of PIP3; Akt, protein kinase
B (T308, S473 – phosphorylated sites threonine 308 and serine 473); FoxO, fork head
transcription factors of O group; GLUT, glucose transporter; GSK3β, glycogen syn-
thase kinase3β; IGF, insulin growth factor; IRS, insulin receptor substrate; mTORC1,
2, mechanistic target of rapamycin complex 1 and 2 (mTOR, formerly known as
mammalian target of rapamycin); PDK2, phosphoinositide dependent kinase2 (a
putative kinase thought to phosphorylate Akt on S473); PI3K, phosphatidylinositol
3-kinases; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol
3,4,5-trisphosphate; PIPDK, phosphoinositide dependent kinase 1 (the abbrevia-
tion PIPDK is preferred over the original PDK1 in the article to avoid confusion
with the pyruvate dehydrogenase kinase, which is also abbreviated as PDK1 in the
literature); rictor, a component of mTORC2; ROS, reaction oxygen species; S6K, the
p70 ribosomal S6K; Sestrins, stress response proteins.
kinase (rac, for related to the A and C protein kinases; RAC-PK)
(Jones et al., 1991); Protein kinase B (between protein kinase A and
C) (Coffer and Woodgett, 1991); or Akt (designated after the onco-
genic provirus, AKT-8) (Bellacosa et al., 1991). Downward (1995)
proposed the use of the kinase name as Akt/PKB to avoid confusion
with Ras related GTPase RAC. The use of Akt has become popu-
lar in literature since then. Structurally, the protein Akt/PKB can
be divided into three regions; the N-terminal pleckstrin homology
containing (AH/PH) domain, the centrally located kinase domain,
and a C-terminal regulatory domain containing the hydropho-
bic motif (HM) phosphorylation site (Nicholson and Anderson,
2002). Akt is activated in response to the insulin or insulin growth
factor signaling (IIS). Akt exists in three isoforms Akt1, 2, 3 with
a varying tissue distribution but with similar domain structure
(Jones et al., 1991; Konishi et al., 2007).
AKT IS THE CENTRAL HUB OF INSULIN/INSULIN GROWTH
FACTOR SIGNALING
Insulin or insulin like growth factor signaling is the major signaling
pathway that responds to the nutrient signals. Insulin is the major
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hormone promoting the anabolic activity in the body. Deregula-
tion of this pathway had been shown to be the principal cause of
the metabolic syndromes like type 2 diabetes, obesity, and can-
cer (Laplante and Sabatini, 2012; Boosani and Agrawal, 2013; Zhu
et al., 2013). White (2003), in his brief review, presented the sum-
mary of events that led to the description of the role of Akt
in insulin signaling pathway (see also the pathway map http://
stke.sciencemag.org/cgi/cm/CMP_12069?cookietest=yes) (White,
2003). In brief, the IIS pathway is activated by the insulin or insulin
like growth factor (IGF) binding to the insulin/IGF receptor, a
hetero-tetramer protein, comprising of two α and two β subunits
spanning across the membrane. Upon stimulation by IGF, the tyro-
sine residues of the cytosolic domains are phosphorylated. This
leads to the recruitment of the key scaffold protein, the insulin
receptor substrate 1 or 2 (IRS 1/2), to the receptor site; IRS in turn
activates the PI3Kinase (PI3K)-Akt pathway.
PHOSPHORYLATION OF AKT IS THE KEY TO ITS ACTIVATION
Akt is phosphorylated at several sites (Mahajan and Maha-
jan, 2012), although the significance of these phosphorylations
remains to be fully understood. Its activity depends on two phos-
phorylated sites; one located in the catalytic domain [also known
as the T- or activation loop, the threonine 308 (Akt T308)] and
the second in the HM, the serine 473 (Akt S473). Insulin was
shown (Kohn et al., 1995) to activate PI3K mediated activation of
Akt. PI3K is a heterodimer consisting of a regulatory p85 subunit
and a catalytic p110 subunit, which mediates the phosphorylation
of phosphoinositides (PIs) at the three-position of the inositol
ring. The enzyme phosphatidylinositol (PI) 3-kinase converts PI
4,5-bisphosphate (PIP2) to the putative second messenger PI 3,4,5-
trisphosphate (PIP3) (Fruman et al., 1998). The AH/PH domain
was shown to be required for the binding of PIs to PH domain and
recruit Akt to the membrane (Franke et al., 1995). There are also
reports that Akt can be translocated to the membrane indepen-
dent of PI3K (Brugge et al., 2007; Mahajan and Mahajan, 2012).
Alessi et al. (1996) identified T308 and S473 phosphorylations
on Akt as the activating sites, and that these phosphorylations do
not depend on one another. A 67 kDa protein was shown to be
responsible for phosphorylation of Akt exclusively on T308 and it
was purified in 1997 from skeletal muscle by Alessi et al. (1997)
and from rat brain by Stokoe et al. (1997), Alessi et al. (1997), and
Stokoe et al. (1997). The kinase was named as 3-phosphoinositide-
dependent protein kinase 1 [PIPDK; the abbreviation PIPDK is
preferred in this article over the original PDK1 (Alessi et al., 1997)
to avoid confusion with the pyruvate dehydrogenase kinase, which
is also abbreviated as PDK1 in the literature]. An unknown kinase,
PDK2, was thought to mediate the S473 phosphorylation. The
identity of this unknown kinase was complicated with reports
that more than ten heterologous kinases were able to phospho-
rylate Akt on Ser 473 (reviewed in Dong and Liu, 2005). Among
the kinases that are reported to phosphorylate Akt S473, there is a
broad consensus, that mTORC2 (mechanistic target of rapamycin
complex 2; mTOR was formerly known as the mammalian tar-
get of rapamycin) could be the kinase that phosphorylates Akt
S473 (Sarbassov et al., 2005). It is reported to phosphorylate Akt
under a variety of physiological conditions (Frias et al., 2006). ILK
was also shown to phosphorylate Akt S473 in association with
rictor and siRNAs against rictor/ILK resulted in inhibition of Akt
S473 (McDonald et al., 2008). But, there is no consistency in the
reports on ILK’s role in this phosphorylation. Chan and Tsichlis
(2001), suggested that ILK could be acting as a scaffold protein. The
double-stranded DNA-dependent protein kinase (DNA-PK) has
gained some acceptance (Feng et al., 2004; Bozulic et al., 2008) as
the possible kinase especially under the conditions of DNA damage
(Stronach et al., 2011). An atypical IκB kinase ε and TANK-binding
kinase 1 (IKKε/TBK1) was also suggested to phosphorylate S473
in rictor−/− cells; it also needed PI3K signaling for activation of
Akt (Xie et al., 2011). Tumor necrosis factor α (TNFα) was ear-
lier reported (O’Toole et al., 2001) to promote phosphorylation
of Akt exclusively on S473. It is reported that inflammation is
associated with hyper active mTORC1 and inhibition of mTORC1
was recently shown to control inflammation (Thiem et al., 2013).
Inhibition of mTORC1 and the presence of rictor is required for
phosphorylation of AktS473 was earlier reported (Breuleux et al.,
2009). It is possible that under the conditions of inhibited state of
rictor by mTORC1, activation of IKKε/TBK1 promotes the phos-
phorylation of Akt S473 for cell survival. TBK1 was recently shown
to be an activator of autophagy in the clearance of Salmonella
enterica (Weidberg and Elazar, 2011).
ROLE OF AKT S473 PHOSPHORYLATION IN CELLULAR
FUNCTION
There are conflicting views on the role of Akt S473 phosphory-
lation in cellular function. It has been suggested that phospho-
rylation of the Ser473 may be independent of its activity (Hill
et al., 2001) or it may not be necessary for the full activation of
Akt (Moore et al., 2011) and that phosphorylation of Thr308 is a
more reliable biomarker than that of Ser473 for Akt activity espe-
cially in tumor samples (Guertin et al., 2006; Vincent et al., 2011).
There is an increasing evidence that selective mTORC1 inhibition
can elicit increased AKT S473 phosphorylation and attenuates the
signal effects on tumor cell proliferation (Guertin et al., 2006; Ike-
noue et al., 2008; Breuleux et al., 2009). It is clear from the foregone
discussion that there is a reciprocal relation between Akt and the
two mTOR complexes. IIS mediated phosphorylation of Akt-T308
activates mTORC1, and mTORC2 phosphorylates Akt on S473.
THE ACTIVATING PHOSPHORYLATIONS OF AKT T308 AND
AKT S473 HAVE DIVERSE DOWNSTREAM EFFECTORS
In most of the phosphoproteomic data on Akt, the two phos-
phorylation sites are shown to be activated concurrently on IIS
signaling and this has led to the suggestion that the phospho-
rylation at two sites is required for its maximal activity, and
IIS stimulates these functions. However, there is a division in
the functional role of Akt in cells and the two phosphorylations
play critical role in this functional division (Chandrasekher and
Sailaja, 2004; Vadlakonda et al., 2013). It has been demonstrated
that, Akt-T308 phosphorylated form is essential and S473 is not
needed for activation of mTORC1 (Guertin et al., 2006; Rodrik-
Outmezguine et al., 2012). mTORC1 activates protein synthesis,
S6K and inhibits autophagy; S6K is a feedback inhibitor of IIS
and represses the rictor/mTORC2 functions. Actively proliferating
cells therefore, require an active mTORC1 to initiate the process
of cell cycle but inhibition of mTORC1 and the activation of
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mTORC2 is required for progression of cell cycle beyond S phase
(Vadlakonda et al., 2013). The phosphorylation status of Akt in
three different types of leukemia presents an interesting case. Taz-
zari et al. (2004) reported high levels of S473 phosphorylation
in acute myeloid leukemia blasts (AML blasts), similarly Nyakern
et al. (2006) reported high levels of Akt S473 phosphorylation in
mononuclear cells from bone marrow of the patients with high-
risk myelodysplastic syndrome (MDS) when compared to normal
or low risk MDS patients; Gallay et al. (2009) on the other hand,
reported higher T308 phosphorylation in patients with AML,
which was shown to be associated with high-risk cytogenetics
and poor overall survival. Although apparently contradictory, the
results reflect the status of proliferation of the cells examined;
actively proliferating AML cases have high T308, while the AML
blasts and MDS, which are poorly dividing cells have high levels of
S473. In our earlier review (Vadlakonda et al., 2013) we suggested
that activation of mTORC2, which is the upstream regulator of
Akt S473, requires inhibition of mTORC1. mTORC2 has two key
functions, phosphorylation of Akt (Sarbassov et al., 2005) and at
the plasma membrane mTORC2 was shown to promote reorga-
nization of cytoskeleton by activating RhoA GTPases and protect
cell survival by up regulating anti-apoptotic proteins, the BCL2
(Goncharova et al., 2011). It is not clear, how these two func-
tions of mTORC2 are partitioned in actively proliferating cells
and quiescent cells. It was shown that mTORC1 activity is needed
for translation of mRNA of RhoA GTPases and for mTORC2
mediated cytoskeleton reorganization (Lee et al., 2012). Akt phos-
phorylated at S473 inhibits FoxO in non-proliferative senescent
cells and there appears to be waves of activation and inactivation
cycles between Akt, mTOR complexes, autophagy, and FoxO in
such cells to keep the survival of the cells intact (Young et al.,
2009). Besides, Akt S473 phosphorylation is needed for uptake
of glucose (Kumar et al., 2010) and the quiescent or senescent
cells require glucose more as they rely on glycolysis for energy
needs. It is coming to be realized that in tumor tissue, there is
a metabolic symbiosis between non-proliferative cells depending
on glucose, while actively proliferating cells on lactate (Semenza,
2008).
THE PRESENCE OF TWO PHOSPHORYLATIONS IN THE
PHOSPHOPROTEOMIC DATA IS A PARADOX!
There is evidence that prior phosphorylation of Akt S473 was
required for enabling PIPDK (PDK1) to phosphorylate at T308
(Scheid et al., 2002; Yang et al., 2002). Sabatini group, who demon-
strated that mTORC2 is the phosphorylating kinase of Akt S473
also confirmed this (Sarbassov et al., 2005). In our previous review
(Vadlakonda et al., 2013), we have shown that Akt S473 phos-
phorylation follows the inhibition of mTORC1, activation (or
reactivation) of FoxO, AMPK, mTORC2, and the progression of
cell cycle. This dichotomy in Akt’s relation with mTOR complexes
is also reflected in other physiological functions of the cells; for
example, anti-apoptotic and proliferative signals from IGF-1 were
shown to bifurcate downstream of PI3K in lens epithelial cells
(Chandrasekher and Sailaja, 2004). IGF-1-mediated stimulation
of the PI3K/p70 S6K cascade was shown to promote cell prolifera-
tion, but inactivation of proapoptotic Bad protein and suppression
of caspase activation was shown to be independent of PI3K/p70
S6K signaling (Chandrasekher and Sailaja, 2004). A similar sit-
uation was also noticed in human non-small cell lung cancer
(Vincent et al., 2011). Akt phosphorylated at T308, primarily tar-
gets TSC2 and PRAS40 leading to the activation of mTORC1, S6K,
and protein synthesis (Kwiatkowski and Manning, 2005), while
Akt phosphorylated at S473 was shown to target mainly the FoxO
proteins (Guo et al., 2006) and promote anti apoptotic and cell
survival pathways (Guan et al., 2011). Akt S473 is a key player in
promoting GLUT4 translocation by phosphorylation of As 160
(Zong et al., 2009; Kumar et al., 2010).
HOW DO THE TWO PHOSPHORYLATED SITES OF AKT
TRANSLATE THEIR MESSAGES TO THE DIVERSE TARGETS?
In our previous review, we suggested that IIS activated PI3K-Akt-
mTORC1 is in fact a negative regulator of mTORC2 and FoxO;
the two complexes, mTORC1 and mTORC2 regulate each other
by a feedback control (Vadlakonda et al., 2013). Such antagonis-
tic relation between mTORC1 and mTORC2 was also recognized
earlier (Breuleux et al., 2009). This raises a question whether Akt
T308 and Akt S473 also regulate each other? In a perspective article
“PDK2: a complex tail in one Akt,” Chan and Tsichlis (2001) pre-
sented evidence that in embryonic stem cells which carry inactive
PDK1 (PIPDK), phosphorylation of T308 has an inhibitory effect
on AktS473 phosphorylation. In a study on pancreatic islet β-cell
specific Rictor and phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) knockout mice (Gu et al., 2011) demon-
strated that βPtenKO mice exhibit a 12-fold increase in AKT-T308
phosphorylation and increase in cell proliferation; rictor null mice
on the other hand, were shown to exhibit reduction in β-cell mass,
mild hyperglycemia, and glucose intolerance Gu et al. (2011). The
authors suggested a critical role for Akt S473 in maintaining the
normal β-cell mass and negatively regulates the T308 phospho-
rylated functions. The two phosphorylations of Akt thus have an
antagonistic effects on each other, but in their review Chan and
Tsichlis (2001) suggested that the interaction of some unknown
molecules in the Akt activation complex might alter its confor-
mation to protect and stabilize the phosphorylations of T308 and
S473 on Akt.
INTER DOMAIN INTERACTIONS ARE KEY IN REGULATION OF
AKT FUNCTIONS
As already indicated, Akt contains three main domains; an N-
terminal pleckstrin homology containing (AH/PH) domain, the
centrally located kinase domain, and a C-terminal regulatory
domain containing the HM phosphorylation site. The presence
of two linker peptides, one between the PH and catalytic domain,
and the other between the catalytic and the c-terminal HM, which
could not be crystallized is a major hindrance in obtaining the
crystal structure of full length Akt protein (Calleja et al., 2009a),
and in studying its inter domain interactions. However, using
combined techniques like protein mass spectrometry, Förster res-
onance energy transfer (FRET) by fluorescence life time imag-
ing microscopy, molecular dynamics, and classical biochemical
approaches (Calleja et al., 2009a,b) proposed that in an inactive
state the PH domain assumes a PH-in conformation and its inter-
action with the catalytic domain creates a cavity, which leads to the
dephosphorylation of the two activating phosphorylations T308
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and S473. Two amino acid residues, tryptophan 80 (W80) in the
PH domain, and phenylalanine 469 (F469) in the hydrophobic
domain interact to keep this inactive state. Upon stimulation by
growth factors, the PH domain assumes the PH-out conformation
and translocation of Akt to plasma membrane induces conforma-
tional changes in the protein facilitating its phosphorylation of the
two activating sites T308 and S473 (Macreadie et al., 1991). Upon
phosphorylation,Akt is detached from the membrane and translo-
cates to the target sites in the cytoplasm and nucleus. In an earlier
study on activation and inactivation dynamics of Akt signaling,
Kunkel et al. (2005) employed biosensors and the real time imag-
ing with FRET, and reported a turnover of the activated Akt with
inactive forms at membrane site and that phosphatases promote
the inactivation of Akt signaling. The inactivation was shown to
be rapid in cytosol when compared to that of the membrane site
or in nucleus.
PHOSPHATASES REGULATE THE AMPLITUDE AND
DURATION OF KINASE ACTIVITY OF AKT
The PTEN, a lipid phosphatase and a tumor suppressor (Maehama
and Dixon, 1998), is one of the key regulators of the PI3K-Akt
pathway. It dephosphorylates the D3 position of phosphatidyli-
nositol (3,4,5)-trisphosphate (PIP3). Mutations resulting in the
functional loss of this phosphatase leading to up regulation of
Akt activity are reported in several cancers (Hollander et al., 2011;
Mester and Eng, 2013). Apart from this, Akt activity itself is shown
to be controlled directly by three phosphatases, the protein phos-
phatase 2A (PP2A) (Resjo et al., 2002) and protein phosphatase 1
(PP1) (Xu et al., 2003; Thayyullathil et al., 2011), and PH domain
leucine-rich repeat protein phosphatase (PHLPP), which is insen-
sitive to okadaic acid and specifically dephosphorylates the S473
(Bayascas and Alessi, 2005; Gao et al., 2005). An increased phos-
phorylation of T308 was shown to be associated with reduced
PP2A in AML patients (Gallay et al., 2009). These phosphatases
also play crucial role in conferring resistance to radiation and
chemo therapies; Eke et al. (2010) recently demonstrated that an
adapter protein, downstream of focal adhesion, PINCH1 [5 Lin-1,
Isl-1, Mec-3 (LIM) domain – containing particularly interesting
new cysteine-histidine-rich 1], inhibits protein phosphatase 1α
and confers resistance to cancer cells against ionizing radiation
and chemo therapies by increasing the Akt phosphorylation.
THE ADENYLATES ATP/ADP MODULATE THE STABILITY OF
AKT PHOSPHORYLATIONS AND DENY ACCESS OF
ACTIVATED AKT TO PHOSPHATASE ACTION
Chan and Tsichlis (2001), in their review, predicted that some
unknown molecules in the Akt activation complex might stabilize
its phosphorylations. In a recent study, two different groups (Chan
et al., 2011; Lin et al., 2012) demonstrated that ATP bound to
the phosphorylated Akt protects the phosphorylated sites by pre-
venting their access to the phosphatases, which in turn results in
increased phosphorylations of these sites. Adenylate nucleotides,
ATP and ADP, were shown to act as “on – off switch” to main-
tain the stability of the phosphorylations at T308 and S473. Both
ATP and the ATP competitive inhibitors were shown to stabilize
the two phosphorylation sites, while hydrolysis of ATP to ADP was
shown to destabilize the kinase and expose the two phosphorylated
sites to phosphatases. Reviewing these two works, Humphrey and
James (2012) suggested that Akt creates a cage in the ATP bound
form between the two phosphorylations in preventing their access
to phosphatases and the stabilized form was shown to detach
from the membrane to be transported to the locations of its tar-
gets. The phosphorylation at T308 was suggested to increase the
affinity between the PH domain and the phosphorylated kinase
domain leading to the detachment of Akt from the membrane
(Ananthanarayanan et al., 2007). Although the question as to how
this stabilization of phosphorylation sites results in the diversi-
fied functions of the Akt remains unanswered, it is not difficult to
speculate that the energy charge and the localization site of its tar-
gets appears to play a critical role in its effects on the downstream
targets.
ENERGY CHARGE (ATP/AMP RATIO) OF CELLS BECOMES
CRUCIAL IN MODULATING AKT’S FUNCTION
The stabilized phosphorylations under ATP/energy rich environ-
ment by activating Akt (Figure 1) primarily target TSC2 and PRAS
40 in cytosol and activate mTORC1 functions. With the reduc-
tion in ATP levels under energy consuming processes activated by
mTORC1, ADP accumulates, and destabilizes the phosphoryla-
tions of Akt; this exposes the phosphorylated sites to phosphatases.
In our previous article (Vadlakonda et al., 2013), we proposed that
the constitution of active mTORC2 takes place only when FoxO,
AMPK, and autophagy are activated and mTORC1 is inhibited.
It is well recognized that activation of AMPK and autophagy and
inhibition of mTORC1take place only when the energy levels in
cells drop (Hardie and Hawley, 2001; Hardie, 2011). The ATP-
ADP switch controlling the stability of Akt therefore, depends
on the energy charge, a concept defined by Atkinson in 1960s
(Ramaiah et al., 1964; Atkinson, 1968). The ratio of concentra-
tion of AMP:ATP which varies at equilibrium as the square of
the ADP:ATP ratio is maintained by the enzyme adenylate kinase,
which is highly expressed in all eukaryotic cells. The role of
AMPK in responding to the equilibrium of adenylate pool and
the equations related to these interactions were discussed in detail
by Hardie and Hawley (2001) and reviewed recently by Oakhill
et al. (2011, 2012). An energy charge of healthy cells is maintained
around 0.9 (10:1) (Hardie and Hawley, 2001); this was shown to
adjust the partitioning of substrates among competing metabolic
functions of energy producing or energy consuming processes
by balancing the feedback regulation cycles (Hardie and Hawley,
2001). Drugs activating AMPK were shown to dephosphorylate
and inactivate Akt but activate the Akt target GSK3 β (King et al.,
2006). This confirms that under high ATP:AMP ratio, the tar-
gets of Akt will be TSC2 and PRAS 40, whose inhibition activates
mTORC1. But under low ATP:AMP ratio, the targets will be the
factors that mobilize resources (glucose) for energy production. It
is therefore not illogical to speculate that the energy dynamics play
critical role in activation inactivation cycles of Akt and modulate
glucose up take.
We present a model below on the interacting dynamics of
the various signal molecules, viz., the Akt, FoxO, AMPK, mTOR
complexes (Figure 1) and how the pathways behave under
energy/nutrient poor, and energy/nutrient surplus environments
(Figure 2).
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FIGURE 1 |The interactions and feedback loops betweenAkt and mTOR
complexes and energy consuming and energy producing processes.
Insulin/insulin growth factor signaling (IIS) activates PI3Kinase, which
phosphorylates PIP2 to PIP3. Binding of PIP3 to AH/PH domain translocates
Akt to the membrane. FoxO transcription factors transcribe rictor leading to
assembly of mTORC2 complex, which phosphorylates Akt S473. Activated by
PIP3, the PIPDK (originally the PDK1) phosphorylates Akt T308. PI3K-Akt
pathway can also be activated independent of IIS (see Mahajan and Mahajan,
2012). The phosphorylations are stabilized by high ATP:AMP ratio, Akt
migrates into cytoplasm and nucleus. In the nucleus it phosphorylates FoxO,
translocates it into the cytoplasm, and under low energy levels AMPK
promotes its translocation into mitochondria. In cooperation with Sirtuin3,
FoxO promotes mitochondrial OXPHOS (Peserico et al., 2013). Sestrins,
transcribed by FoxO inhibit mTORC1 and the energy consuming processes
come down. This up regulates ATP:AMP ratio. At basal level of activation, Akt
inhibits AS 160 and activates translocation of glucose transporter (GLUT4) to
the membrane there by facilitating the glucose entry into the cells. Activated
AMPK also promotes glucose transport under low energy conditions
(Schwenk et al., 2010; Wu et al., 2013). The cycle continues under healthy
environments. Under inflammatory environment, either due to the Dietary
surplus environment or under stress activated conditions, the IIS is
destabilized and causes insulin resistance (see Figure 2).
THE MODEL
A simplified sequence of events of phosphorylation/dephosphoryl
ation or activation/inactivation cycles of Akt vis-a-vis the mTOR
complexes can be described as hereunder.
Under energy/nutrient depleted conditions, Akt is in an
inhibited state; FoxO and AMPK transcription factors are
activated. AMPK activates glycolysis and krebs cycle and gener-
ates ATP, but inhibits mTORC1 (Hardie and Hawley, 2001; Liang
and Mills, 2013). AMPK also activates autophagy, which recycles
the cellular cargo and degrades defective/damaged mitochondria
in cells starved of energy (Egan et al., 2011; Hardie, 2011). Within
the nucleus, the activation of FoxO leads to transcription of rictor
(Chen et al., 2010), IRS (Tsunekawa et al., 2011; Tsuchiya et al.,
2012) and enzymes of gluconeogenesis (Zhang et al., 2006; Liu
et al., 2011; Shin et al., 2012). Amino acids released from recy-
cled cargo by autophagy release the inhibition on mTORC1 by
AMPK and provide the substrates for protein synthesis needed for
the reprogramming of metabolism. Activation of mTORC1 also
facilitates the translation of transcription products of FoxO like
rictor and IRS. The protein rictor promotes the constitution of
mTORC2 which then translocates to membrane to activate the
Akt S473 phosphorylation (see the text). Since insulin or IGFs are
absent under nutrient deprived conditions, it is probable that Akt
is activated independent of PI3K/insulin signaling (Brugge et al.,
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FIGURE 2 | Schematic representation of interacting signal pathways
under (A) dietary restriction and healthy environment and (B) under
dietary surplus and stress environment. The interactions between FoxO,
Akt, mTORC1, and C2, as well as those of AMPK and metabolism are shown
under dietary restriction and dietary surplus conditions. (For abbreviations see
the text.)
2007; Mahajan and Mahajan, 2012). Activated Akt is liberated from
the membrane and migrates into cytoplasm and nucleus. In the
cytoplasm it phosphorylates As 160, which leads to translocation
of GLUT4 to the membrane. It has been shown that both Akt S473
and mTORC2 are key factors in GLUT4 translocation (Zong et al.,
2009; Kumar et al., 2010; Fukuda, 2011; Kim et al., 2011). Within
the nucleus, Akt phosphorylates FoxO, which then translocates
into the cytoplasm (Guertin et al., 2006). In the cytoplasm, active
AMPK drives FoxO into the mitochondria and in cooperation with
the SIRTUIN3 activates mitochondrial respiration (Peserico et al.,
2013).
This increases production of ATP,raising the levels of ATP/AMP
ratio. Enhanced ATP/AMP ratio stabilizes Akt, which targets TSC2,
PRAS40; this results in further activation of mTORC1. Cou-
pled with the exclusion of FoxO from the nucleus, activation
of mTORC1 leads to the inhibition of rictor and disassembly
mTORC2, which reduces the mTORC2 mediated S473 phospho-
rylation of Akt and release of inhibition on AS 160 and making
GLUT4 dysfunctional.
THE NUTRIENT STATUS OF ORGANISMS APPEARS TO PLAY A CRITICAL
ROLE IN THIS ENERGY AND SIGNALING DYNAMICS
Under dietary restriction, limited entry of glucose keeps the rise
in ATP:AMP ratio at the bare minimum levels to maintain liv-
ing processes, mTORC1 remains largely inhibited and IIS is not
in the picture (Mercken et al., 2013). When the nutrients are
maintained in a balanced state, especially during the growth phase
of the organisms, the energy expenditure due to active mTORC1
reduces the ATP/AMP ratio destabilizing Akt and the alternate
activation, reactivation cycle of Akt, and glucose entry regulate IIS.
Higher activation of mTORC1 due to enriched nutrients/amino
acids inside the cells might lead to inhibition of rictor (mTORC2)
and a feedback inhibition of IIS (see the text). Inhibition of
autophagy/mitophagy by mTORC1 will also produce reaction oxy-
gen species (ROS) and create conditions of inflammation (Thiem
et al., 2013). It is possible that when ROS generated during active
biosynthetic processes are under control, the protective phase of
inflammation might lead to activation of cytokines and TNFα,
and promote phosphorylation of AktS473 exclusively even in the
absence of mTORC2 (O’Toole et al., 2001). This retains the GLUT4
active at the membrane and promotes the replenishment of glu-
cose in the cell for ATP production. But under malnutrition and
surplus nutrients, especially in aging organisms, the deregulation
of Akt activation, deactivation cycles promote the stress activated
state. Increased levels of cytokines and stress activated kinases
like JNK (Salminen and Kaarniranta, 2013) under such situations
hampers both IIS and the glucose flux resulting in the state of
insulin resistance (Figure 2).
CONCLUSION
In summary, we suggest that the nutrient inputs, energy cycles reg-
ulate the functions of several signal molecules. Akt is positioned
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at the central hub of regulating these interactions. The reciprocal
relation that exists between the two activating phosphorylation
sites, T308 and S473, of Akt and the two mTOR complexes, C1 and
C2, forms the central controlling hub that regulates cellular func-
tion. The energy charge, the ratio of concentration of ATP to that of
AMP, decides the active and inactive state of Akt. In general, the sta-
bility of Akt phosphorylations is coupled to high ATP:AMP ratio
in cells. It activates mTORC1 and the energy consuming biosyn-
thetic processes. Under nutrient deprived conditions, active FoxO
transcribes rictor promoting constitution of mTORC2; phospho-
rylation of T308 and activation of Akt may be independent of
IIS and Akt maybe stable for short time, which is required for
maintenance of basal metabolism.
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